» Articles » PMID: 25262586

Insular Infarct Size but Not Levosimendan Influenced Myocardial Injury Triggered by Cerebral Ischemia in Rats

Overview
Journal Exp Brain Res
Specialty Neurology
Date 2014 Sep 30
PMID 25262586
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Cerebral injuries can trigger stress-related cardiomyopathy. The extent of cerebral injury and the involvement of the insular cortex influence the incidence and extent of myocardial injury (MI), and drugs with proven neuroprotective and cardioprotective properties such as levosimendan might be beneficial. This hypothesis was addressed in a rat model of transient middle cerebral artery occlusion. Transient brain ischemia was induced for 60 min by intraluminal occlusion of the middle cerebral artery in 40 male Wistar rats. Treatment with levosimendan (24 µg/kg) was started briefly before reperfusion. Hemodynamic parameters were recorded and cerebral and MI quantified after 24 h. Levosimendan treatment significantly reduced cerebral infarct size in the cortex, but not in the striatal and insular regions. However, its effects on survival (28 vs. 45%), incidence of MI (8 vs. 33%) as indicated by a troponin I (sTnI) threshold of 4.8 µg/L and large insular infarcts of ≥10 mm(3) (23 vs. 50%) failed to reach statistical significance. Blood pressure demonstrated significant differences related to insular infarct size during reperfusion. Levosimendan demonstrated no relevant effects on markers of MI (sTnI = 1.5 ± 2.8 vs. 5.3 ± 7.2 µg/L, P = 0.121). Insular infarct size could be identified as the only predictor of MI (odds ratio = 1.86, P = 0.037). In conclusion, the current investigation confirmed insular infarct size as a predictor of MI and source of hemodynamic compromise, but failed to demonstrate an effect of levosimendan on MI trigged by brain ischemia. A hardly protectable insular region might explain this.

Citing Articles

Predictive Value of NT-proBNP for Functional Outcome of Ischemic Stroke Without Cardiac Disease: A Prospective, Observational Study.

Liu R, Chen G, Zhao N, Yue W Neuropsychiatr Dis Treat. 2025; 21:129-140.

PMID: 39897711 PMC: 11784306. DOI: 10.2147/NDT.S488574.


Stroke-heart syndrome: current progress and future outlook.

Wang L, Ma L, Ren C, Zhao W, Ji X, Liu Z J Neurol. 2024; 271(8):4813-4825.

PMID: 38869825 PMC: 11319391. DOI: 10.1007/s00415-024-12480-4.


Emerging Strategies and Effective Prevention Measures for Investigating the Association Between Stroke and Sudden Cardiac Fatality.

Kumar H, Jeevanandham S, Ganesh M, Sabana M, Manivasakam P Curr Cardiol Rev. 2024; 20(3):35-44.

PMID: 38310557 PMC: 11284691. DOI: 10.2174/011573403X259676231222053709.


The Heart Is at Risk: Understanding Stroke-Heart-Brain Interactions with Focus on Neurogenic Stress Cardiomyopathy-A Review.

Ziaka M, Exadaktylos A J Stroke. 2023; 25(1):39-54.

PMID: 36592971 PMC: 9911836. DOI: 10.5853/jos.2022.02173.


Stroke-Heart Syndrome: Recent Advances and Challenges.

Scheitz J, Sposato L, Schulz-Menger J, Nolte C, Backs J, Endres M J Am Heart Assoc. 2022; 11(17):e026528.

PMID: 36056731 PMC: 9496419. DOI: 10.1161/JAHA.122.026528.

References
1.
Ryang Y, Dang J, Kipp M, Petersen K, Fahlenkamp A, Gempt J . Solulin reduces infarct volume and regulates gene-expression in transient middle cerebral artery occlusion in rats. BMC Neurosci. 2011; 12:113. PMC: 3251036. DOI: 10.1186/1471-2202-12-113. View

2.
Memezawa H, Minamisawa H, Smith M, Siesjo B . Ischemic penumbra in a model of reversible middle cerebral artery occlusion in the rat. Exp Brain Res. 1992; 89(1):67-78. DOI: 10.1007/BF00229002. View

3.
Izumi Y, Okatani H, Shiota M, Nakao T, Ise R, Kito G . Effects of metoprolol on epinephrine-induced takotsubo-like left ventricular dysfunction in non-human primates. Hypertens Res. 2009; 32(5):339-46. DOI: 10.1038/hr.2009.28. View

4.
Rincon F, Dhamoon M, Moon Y, Paik M, Boden-Albala B, Homma S . Stroke location and association with fatal cardiac outcomes: Northern Manhattan Study (NOMAS). Stroke. 2008; 39(9):2425-31. PMC: 4112463. DOI: 10.1161/STROKEAHA.107.506055. View

5.
Talan M, Ahmet I, Xiao R, Lakatta E . β₂ AR agonists in treatment of chronic heart failure: long path to translation. J Mol Cell Cardiol. 2010; 51(4):529-33. PMC: 3051013. DOI: 10.1016/j.yjmcc.2010.09.019. View